Haaning
Jesper Haaning, Birkeroed DK
Patent application number | Description | Published |
---|---|---|
20140018297 | COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA - The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound. | 01-16-2014 |
20150045303 | Pharmaceutical Composition Suitable for Treatment of Haemophilia - The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia. | 02-12-2015 |
20150080309 | Compounds Suitable for Treatment of Haemophilia - The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases. | 03-19-2015 |
Jesper Mortensen Haaning, Birkeroed DK
Patent application number | Description | Published |
---|---|---|
20090017499 | RANK LIGAND-BINDING POLYPEPTIDES - The present invention relates to a polypeptide having an amino acid sequence that differs from and is at least 70% identical to the amino acid sequence of hRANK, and which has a binding affinity to RANKL that is at least as high as the binding affinity of hRANK to RANKL, as determined by the functional competition assay described herein. | 01-15-2009 |
20100330669 | FVII OR FVIIA VARIANTS - Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237, or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa. | 12-30-2010 |
Jesper Mortensen Haaning, Redwood City, CA US
Patent application number | Description | Published |
---|---|---|
20100260741 | Factor VII or VIIa Polypeptide Variants - The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma. | 10-14-2010 |